Actively Recruiting
Registry Study of Cerebral Small Vessel Disease
Led by Dongzhimen Hospital, Beijing · Updated on 2026-01-15
50
Participants Needed
1
Research Sites
59 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The incidence of cerebral small vessel disease (CSVD) increases with age, affecting approximately 5% of individuals over 50 years old and nearly all individuals over 90 years old. CSVD is also the most important vascular factor contributing to cognitive decline, with 45% of dementia patients attributed to CSVD. Existing interventions are similar to secondary prevention strategies for cardiovascular and cerebrovascular diseases, and no specific therapies are currently available. CSVD-related cognitive impairment (CSVDCI) predominantly involves attention, processing speed, and executive functions, with relatively preserved memory function, and may be accompanied by non-cognitive clinical manifestations such as gait disturbances, emotional and behavioral disorders, and bladder dysfunction. Although CSVDCI can be classified under vascular cognitive impairment (VCI), there are certain differences in its clinical manifestations. In summary, it is necessary to develop more targeted treatments for CSVD. We attempt to establish a "symptom-tongue coating-gut microbiota-imaging" system to provide data support for the subsequent exploration of CSVD treatments based on traditional Chinese medicine (TCM) syndrome differentiation and treatment.
CONDITIONS
Official Title
Registry Study of Cerebral Small Vessel Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age above 50 years (including 50-year-old)
- MRI confirmed the presence of typical imaging changes of CSVD
- Voluntary participation in the study and willing to sign the Informed Consent Form
You will not qualify if you...
- Acute ischemic stroke or acute intracranial hemorrhage or history of cerebral infarction (non-lacunar) or intracranial hemorrhage within past 3 months
- Significant non-vascular white matter lesions such as multiple sclerosis, adult-onset leukoencephalopathy, or metabolic encephalopathy
- History of cognitive impairment due to other causes including normal pressure hydrocephalus, Alzheimer's disease, Parkinson's disease, multiple sclerosis, or encephalitis
- Severe liver, kidney, or heart failure (ALT or AST >2 times upper limit, serum creatinine >1.5 times upper limit, or NYHA functional class III or IV)
- Psychiatric disorders affecting medication administration or evaluation
- Contraindications to MRI such as claustrophobia or presence of an implantable pacemaker
- Unable to comply with follow-up or study procedures due to location or other reasons
- Participation in other clinical trial projects
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700
Beijing, Beijing Municipality, China
Actively Recruiting
Research Team
B
Beida Ren, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here